Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

GeoVax Partners With French Firm

July 25, 2008

On Thursday, Atlanta-based GeoVax Labs Inc. announced a new partnering agreement under which a component of its candidate HIV vaccine will be manufactured by the French firm Vivalis. GeoVax has reported progress toward Phase II preventive clinical human trials of its vaccine and plans to move into therapeutic human trials this fall, said Robert McNally, its president and CEO. The Phase II trial will be conducted by the National Institutes of Health with the support of the HIV Vaccine Trials Network. It will involve 225 healthy volunteers from the United States and South America.

Back to other news for July 2008

Adapted from:
Atlanta Journal-Constitution
07.25.2008; Bill Hendrick


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement